Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Editas Medicine (EDIT) Return on Capital Employed (2016 - 2025)

Historic Return on Capital Employed for Editas Medicine (EDIT) over the last 10 years, with Q3 2025 value amounting to 1.38%.

  • Editas Medicine's Return on Capital Employed fell 5700.0% to 1.38% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.38%, marking a year-over-year decrease of 5700.0%. This contributed to the annual value of 0.73% for FY2024, which is 3500.0% down from last year.
  • Editas Medicine's Return on Capital Employed amounted to 1.38% in Q3 2025, which was down 5700.0% from 1.4% recorded in Q2 2025.
  • Editas Medicine's Return on Capital Employed's 5-year high stood at 0.24% during Q1 2021, with a 5-year trough of 1.4% in Q2 2025.
  • Moreover, its 5-year median value for Return on Capital Employed was 0.46% (2024), whereas its average is 0.59%.
  • In the last 5 years, Editas Medicine's Return on Capital Employed soared by 1400bps in 2021 and then tumbled by -7700bps in 2025.
  • Editas Medicine's Return on Capital Employed (Quarter) stood at 0.3% in 2021, then tumbled by -64bps to 0.49% in 2022, then rose by 21bps to 0.39% in 2023, then plummeted by -153bps to 0.98% in 2024, then crashed by -41bps to 1.38% in 2025.
  • Its Return on Capital Employed stands at 1.38% for Q3 2025, versus 1.4% for Q2 2025 and 1.13% for Q1 2025.